To view our product pipeline, follow this link.
Our product development strategy is focused on developing products with a predicted high return on investment and a low cost of development.
We focus exclusively on topically applied pharmaceutical drugs and medical devices. We only incorporate existing chemical entities into our products. This strategy enables us to offer an overall lower risk profile compared with developing new chemical entities. As a result, the overall risk of the investment is reduced as our strategy increases the likelihood of regulatory approval and lowers the cost of development.
We have five products in our development pipeline for sexual healthcare and pain relief management: CSD500, PET500, MED2002, TPR100 and RAD100.
SSL has global distribution rights for our condom product CSD500. We also have with SSL a global development and licensing agreement for MED2002. In addition, we are in non-exclusive discussions for the distribution rights to our product for topical pain relief TPR100 and to our product for premature ejaculation PET500.
We are evaluating further product opportunities for our proprietary delivery system DermaSys® with a range of other compounds.
